JP2005034151A - 癌を評価および治療する方法 - Google Patents

癌を評価および治療する方法 Download PDF

Info

Publication number
JP2005034151A
JP2005034151A JP2004195973A JP2004195973A JP2005034151A JP 2005034151 A JP2005034151 A JP 2005034151A JP 2004195973 A JP2004195973 A JP 2004195973A JP 2004195973 A JP2004195973 A JP 2004195973A JP 2005034151 A JP2005034151 A JP 2005034151A
Authority
JP
Japan
Prior art keywords
fti
patient
treatment
chlorophenyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004195973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005034151A5 (OSRAM
Inventor
Mitch Raponi
ラポーニ ミッチ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Diagnostics LLC
Original Assignee
Veridex LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veridex LLC filed Critical Veridex LLC
Publication of JP2005034151A publication Critical patent/JP2005034151A/ja
Publication of JP2005034151A5 publication Critical patent/JP2005034151A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2004195973A 2003-07-01 2004-07-01 癌を評価および治療する方法 Pending JP2005034151A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61144603A 2003-07-01 2003-07-01

Publications (2)

Publication Number Publication Date
JP2005034151A true JP2005034151A (ja) 2005-02-10
JP2005034151A5 JP2005034151A5 (OSRAM) 2007-11-08

Family

ID=33541317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004195973A Pending JP2005034151A (ja) 2003-07-01 2004-07-01 癌を評価および治療する方法

Country Status (9)

Country Link
EP (1) EP1502962A3 (OSRAM)
JP (1) JP2005034151A (OSRAM)
KR (1) KR20050004076A (OSRAM)
CN (1) CN1626679A (OSRAM)
AR (1) AR044984A1 (OSRAM)
AU (1) AU2004202980B2 (OSRAM)
BR (1) BRPI0403291A (OSRAM)
CA (1) CA2472846A1 (OSRAM)
MX (1) MXPA04006494A (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014525269A (ja) * 2011-08-30 2014-09-29 ディーシービー−ユーエスエー エルエルシー 卵巣新生物に対する易罹患性及び／又は卵巣がんの予後若しくは悪性度を予測する方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050003422A1 (en) * 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
AR048945A1 (es) * 2004-05-06 2006-06-14 Veridex Llc Pronostico para leucemia mieloide cronica
WO2006124836A1 (en) * 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
US20110009387A1 (en) * 2007-06-12 2011-01-13 Andrea Dawn Basso-Porcaro Histone h2ax (hh2ax) biomarker for fti sensitivity
CN109628591B (zh) * 2018-12-04 2022-04-15 南方医科大学南方医院 用于肺腺癌预后预测的标志物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003038129A2 (en) * 2001-10-30 2003-05-08 Ortho-Clinical Diagnostics, Inc. Methods for assessing and treating leukemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003038129A2 (en) * 2001-10-30 2003-05-08 Ortho-Clinical Diagnostics, Inc. Methods for assessing and treating leukemia

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014525269A (ja) * 2011-08-30 2014-09-29 ディーシービー−ユーエスエー エルエルシー 卵巣新生物に対する易罹患性及び／又は卵巣がんの予後若しくは悪性度を予測する方法

Also Published As

Publication number Publication date
CA2472846A1 (en) 2005-01-01
AU2004202980B2 (en) 2009-05-07
CN1626679A (zh) 2005-06-15
AU2004202980A1 (en) 2005-01-20
KR20050004076A (ko) 2005-01-12
AR044984A1 (es) 2005-10-12
EP1502962A2 (en) 2005-02-02
EP1502962A3 (en) 2006-01-11
MXPA04006494A (es) 2005-04-19
BRPI0403291A (pt) 2005-07-12

Similar Documents

Publication Publication Date Title
EP3198026B1 (en) Method of determining pik3ca mutational status in a sample
Masui et al. Molecular pathology in adult high‐grade gliomas: from molecular diagnostics to target therapies
US9434994B2 (en) Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by non-small cell lung cancer patients
EP1824997B1 (en) Genetic alteration useful for the response prediction of malignant neoplasia to taxane-based medical treatment
EP3325661B1 (en) Fgfr expression and susceptibility to an fgfr inhibitor
CA2755260C (en) Method for determining sensitivity to irinotecan and use thereof
US8216783B2 (en) Over-expression and mutation of a tyrosine kinase receptor FGFR4 in tumors
EP1611890B1 (en) Methods for assessing and treating cancer
JP2005333987A (ja) 悪性血液疾患の予後
US12391985B2 (en) Method of determining PIK3CA mutational status in a sample
JP2022523773A (ja) がんの予後及び治療におけるａｐｏｅ遺伝子型決定
JP2008523822A (ja) 急性骨髄性白血病患者を評価するための方法
US20120095030A1 (en) Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors
AU2004202980B2 (en) Methods for assessing and treating leukemia
MX2014006186A (es) Capacidad de respuesta a los inhibidores de la angiogenesis.
EP2732287B1 (en) Methods of prognosing chronic lymphocytic leukemia
WO2012139945A1 (en) Method for predicting survival in cancer patients
WO2026050734A1 (en) Method of treating and diagnosing cancers
AU2014213541B2 (en) Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
HK1241934A1 (en) Method of determining pik3ca mutational status in a sample
HK1241934B (en) Method of determining pik3ca mutational status in a sample
HK1256118B (en) Fgfr expression and susceptibility to an fgfr inhibitor
HK1195342A (en) Method for predicting risk of hypertension associated with anti-angiogenesis therapy
HK1196976A (en) Responsiveness to angiogenesis inhibitors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100420

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100928